On the recordMay 22, 2018
This that I am proposing today would be the final amendment to the bill, which will not kill the bill or send it back to committee. If adopted, the bill will immediately proceed to final passage, as amended, and this amendment would offer a more targeted approach to improve FDA's expanded access program that allows patients access to experimental drugs that can possibly save their lives, which is the goal of all of us. {time} 1645 The FDA ensures that expanded access requests are safe, and it approves nearly 100 percent of all the requests that are made, and most in a matter of hours, if necessary. The right-to-try legislation we are considering today presents a huge risk to patients and is much worse than the House bill we passed in March, as our ranking member explained. If this bill is so good, why are 104 patient groups--these are the groups that represent the sick and dying people--opposed? And PhRMA, the big pharmaceutical companies, are not supportive because this gives open license to snake oil salesmen. This bill exposes far more patients to serious risks through a dangerous and unnecessary pathway for experimental treatment.…
Source
govinfo.gov




